C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

EstablishedExclusive Licensing Agreement for CFT8919, an EGFR L858R BiDAC™ Degrader, with Betta Pharmaceuticals in Greater China for NSCLC; U.S. IND Cleared

Related Keywords

China ,Taiwan ,United States ,Macau ,Hong Kong ,American ,Courtney Solberg ,Mary Christian ,Andrew Hirsch ,Loraine Spreen ,Len Reyno ,Leonard Len Reyno ,Therapeutics Inc ,Exchange Commission ,Drug Administration ,International Conference On Malignant Lymphoma ,Development Rd Expense ,Betta Pharmaceuticals ,Betta Pharmaceuticals In Greater China ,American Society Of Clinical Oncology ,Leadership Team ,Corporate Communications Patient Advocacy ,Establishedexclusive Licensing Agreement ,Greater China ,Escalation Data Expected ,Chief Medical Officer ,Senior Vice President ,Cash Equivalents ,Marketable Securities Total ,Provide Runway ,New Preclinical Data ,International Conference ,Malignant Lymphoma ,Progress Poster ,Clinical Oncology ,Annual Meeting ,Licensing Agreement ,New Drug ,Application Clearance Achieved ,Betta Pharmaceutical Phase ,Present Phase ,Net Loss ,Financial Guidance ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,Consolidated Statement ,Months Ended June ,Corporate Communications ,Patient Advocacy ,Region ,